Innoviva (INVA) Retained Earnings (2010 - 2026)
Innoviva's (INVA) quarterly Retained Earnings came in at $456.0 million in Q1 2026, up 1042.44% YoY from $39.9 million in Q1 2025, and up 69.27% on a QoQ basis from $269.4 million in Q4 2025.
Analysis
Innoviva (INVA) Retained Earnings (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Retained Earnings data on file, last reported at $456.0 million in Q1 2026.
- Quarterly Retained Earnings rose 1042.44% year-over-year to $456.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $456.0 million (up 1042.44% YoY) and the FY2025 annual result came in at $269.4 million, up 15089.87% from the prior year.
- Retained Earnings advanced to $456.0 million in Q1 2026, from $269.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $456.0 million in Q1 2026 to a low of -$204.9 million in Q4 2022.
- A 5-year average of -$2.0 million and a median of -$23.3 million in 2024 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 15089.87% in 2025, down 526.53% in 2025.
- Tracing INVA's Retained Earnings over 5 years: stood at -$204.9 million in 2022, then soared by 87.71% to -$25.2 million in 2023, then soared by 92.87% to -$1.8 million in 2024, then soared by 15089.87% to $269.4 million in 2025, then soared by 69.27% to $456.0 million in 2026.
- The last three Retained Earnings figures came in at $456.0 million (Q1 2026), $269.4 million (Q4 2025), and $105.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | 372.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 372.54 Mn |
| Mar 31, 2026 | 455.96 Mn |
| Dec 31, 2025 | 269.37 Mn |
| Sep 30, 2025 | 105.22 Mn |
| Jun 30, 2025 | 15.31 Mn |
| Mar 31, 2025 | -48.38 Mn |
| Dec 31, 2024 | -1.80 Mn |
| Sep 30, 2024 | -22.13 Mn |
| Jun 30, 2024 | -23.34 Mn |
| Mar 31, 2024 | 11.34 Mn |
| Dec 31, 2023 | -25.19 Mn |
| Sep 30, 2023 | -86.72 Mn |
| Jun 30, 2023 | -168.77 Mn |
| Mar 31, 2023 | -170.05 Mn |
| Dec 31, 2022 | -204.91 Mn |
| Sep 30, 2022 | -136.60 Mn |
| Dec 31, 2021 | -456.15 Mn |
| Sep 30, 2021 | -466.49 Mn |
| Jun 30, 2021 | -538.93 Mn |
| Mar 31, 2021 | -627.88 Mn |